Front Bioeng Biotechnol
August 2024
Advancements in cell therapy have the potential to improve healthcare accessibility for eligible patients. However, there are still challenges in scaling production and reducing costs. These challenges involve various stakeholders such as the manufacturing facility, third-party logistics (3PL) company, and medical center.
View Article and Find Full Text PDFNeutral and deprotonated anionic Ni(II), Pd(II), Cu(II), and Cu(III) complexes of tetrakis(perfluorophenyl)-N-confused porphyrin (PF-NCP) were prepared and investigated by UV-visible and magnetic circular dichroism (MCD) spectroscopies. As in the previously reported Ni(II) adduct of tetraphenyl N-confused porphyrin, we observe sign reverse (positive to negative intensities with increasing energy) features in the MCD spectra of the neutral Ni(II), Pd(II), and Cu(II) complexes of PF-NCP, which is indicative of rare ΔHOMO < ΔLUMO relationships. Upon deprotonation of Ni(II), Pd(II), and Cu(II) complexes, these features revert to those of more typical porphyrin MCD spectra consistent with a ΔHOMO > ΔLUMO condition.
View Article and Find Full Text PDF